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Abstract 
This study is a part of a project investigating the molecular determinants of neurological diseases. To account 
for the systemic nature of these diseases we proceeded from a well established list of 38 schizophrenia-related 
genes (Allen et al., 2008; Ross et al., 2006) and investigated their closest network environment. The created 
networks were compared to recently proposed list of 173 schizophrenia related genes (Sun et al., 2009). 115 
genes were predicted as potentially related to schizophrenia and subjected to GSEA. The enriched groups of 
proteins included neuromodulators, neurotransmitters and lipid transport. Over 100 signaling pathways were 
found significantly involved, signal transduction emerging as the most highly significant biological process. 
Next, we analyzed two microarray expression datasets derived from olfactory mucosa biopsies of 
schizophrenic patients and postmortem brain tissue samples from SMRIDB. The systems biology analysis 
resulted in a number of other genes predicted to be potentially related to schizophrenia, as well as in additional 
information of interest for elucidating molecular mechanisms of schizophrenia. 
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1 Introduction 
Schizophrenia is a severe, chronic and disabling mental disorder that affects about 1 percent of the human 
population worldwide. It is a complex disorder that has increasingly been recognized as a collection of 
different disorders including cognitive, social and emotional deficits. Previous studies suggests that there are 
lot of factors including heritability, genetic vulnerability, environmental influences, disruption in various 
neurotransmitter systems making schizophrenia a dynamic disorder leading to the deregulation of multiple 
pathways. Other mechanistic hypotheses have been related to immune system disorder, early 
neurodevelopmental interference, GABAergic, dopamine, and glutamatergic dysfunction. More recent 
molecular findings suggested that a complex interplay between receptors, kinases, proteins and hormones takes 
place in schizophrenia (Lang et al., 2007). Recently, pathway and gene network analysis (Ferrarini, 2011) were 
suggested to be a powerful tool in uncovering molecular mechanisms of complex disorder like schizophrenia 
(Jia et al., 2009; Sun et al., 2010; Rietkerk et al., 2009).  
          This study is the first part of a project investigating and comparing the molecular determinants of 
neurological diseases using gene network analysis. In order to account for the systemic nature of these diseases 
we proceeded from a well established "core" list of 38 schizophrenia-related genes/proteins (Allen et al., 2008; 
Ross et al., 2006), and investigated their closest network environment as a first step in defining  the entire Network Biology, 2012, 2(1):16-25 
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space of  such genes. The expanded set of genes were then compared to the recently published list of 173 
genes potentially related to schizophrenia (Sun et al., 2009) and a number of new such genes were identified 
and subjected to Gene Set Enrichment Analysis (GSEA; Mootha et al. 2003; Subramanian et al. 2005). Next, 
we analyzed two microarray expression datasets (Matigian et al., 2010; Higgs et al., 2006). These datasets 
provided experimental validation of genes predicted by our systems biology approach. We thus utilized both 
computational and experimental datasets to generate new information of potential interest for the molecular 
mechanisms of the schizophrenia disorder. 
 
2 Methods 
2.1 Construction of networks 
The latest version 8.0 of the Pathway Studio software (Ariadne Genomics, 2010) was applied to build several 
networks in which the core 38 selected proteins were connected either down the shortest paths between them 
or with proteins they target or with proteins which regulate them. A "new" set of potential schizophrenia-
related genes was thus created from the closest environment of the 38 well-known schizophrenia-related genes. 
As shown in Fig. 1, this new set was then compared with the recently proposed extended list of 173 genes 
potentially related to schizophrenia (Sun et al., 2009). We ended up with a list of 115 predicted genes after 
discarding genes with local connectivity (node degree) less than three. These genes were then subjected to 
GSEA analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 The study workflow chart. SRGs - Schizophrenia-related genes; NWs - Networks 
 
 
38 SRGs  
(Allen et al., 2008; Ross et al., 2006)
SP, CT, CR Neighborhood NWS and GSEA
815 SRGs from Neighborhood NWs 
Subtracted 53 overlapping genes 
Set of 173 predicted SRGs  
(Sun et al., 2009) 
Eliminated 637 genes having 1 or 2 neighbors 
2487 genes-olfactory mucosa 
biopsy (Matigian et al., 2010) 
115 predicted genes 
Eliminated 10 duplicates 
1071 genes-post-mortem brain 
tissue (Higgs et al., 2006) 
22 validated new SRGs 11 validated new SRGS 
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2.2 Microarray expression datasets 
We utilized two publicly available microarray expression datasets to examine how well our 115 selected genes 
were experimentally represented. The first one was derived from olfactory mucosa biopsy samples (for more 
details see Matigian et al., 2010) and includes 42 samples from control, Schizophrenia and Parkinson subjects. 
For our analysis, we used the data of nine control and Schizophrenia subjects, matched by age and gender. The 
dataset was downloaded from the ArrayExpress database; accession number E-TABM-724.   
(http://www.ebi.ac.uk/arrayexpress) 
The second microarray expression dataset was post-mortem brain tissue samples from The Stanley Medical 
Research – Online Genomics Database (SMRIDB) (https://www. stanleygenomics.org/) (Higgs et al., 2006). 
For our analysis, we used the expression dataset from Study ID: 5 (Investigator: Dobrin), from which we 
selected 20 age- and gender-matched samples of control and Schizophrenia subjects.  
For both microarray expression datasets, we applied the latest version 8.0 of the Pathway Studio software, 
and investigated the gene expression patterns, and network environment. Enriched canonical pathways and 
biological functions were identified using Ingenuity Pathway Analysis (IPA version 9.0). 
  
3 Results and Discussion 
3.1 Prediction and ontology analysis of potential schizophrenia-related genes 
As shown in the Workflow Chart (Fig. 1), 115 genes were predicted as potentially related to Schizophrenia. 
The close network environment of these genes was constructed and analyzed using Pathway Studio software 
version 8.0. Almost all of the 115 genes interact with each other directly. TP53, SRC, MAPK1, ESR1, EP300, 
STAT3, CAV1, CREB1, CASP3, and MAPK3 were the top 10 highly connected nodes in the shortest-path 
network. Different MAP kinases were found to be both highly targeted and regulators of other targets. Apart 
from the MAP kinases, SRC, EP300, CREB1, CASP3, and CEBPA were among the highly targeted genes, 
while SRC, CTNNB1, ESR1, STAT3, MAPT, PTK2, and CREB1 were major regulators. 
The 115 genes were also subjected to GSEA analysis using Pathway Studio 8.0. The significantly enriched 
groups of proteins included among others neuromodulators and neurotransmitters, as well as lipid transport, 
known to be of importance in schizophrenia. Over 100 signaling pathways were found to be significantly 
involved, with the dominance of MAP kinases and other signaling pathways such as STAT, CTNNB, 
CEBPA/FOXO1A, FOXO/MYCN. Genes like CREB1, SHC1, RAF1, RPS6KA5, PLCG1, PIK3R1, were 
found in high frequency in the top 20 signaling pathways. Signal transduction emerged as the most highly 
significant biological process. Protein amino acid phosphorylation, response to glucocorticoid stimulus, 
sensory perception of pain and Ras protein signal transduction were some of the other schizophrenia-related 
significant biological process. Cellular components of high significance included among others axon, neuron 
projection, dendrite and dendrite cytoplasm, and presynaptic membrane. 
3.2 Validation of the set of 115 predicted genes by the olfactory mucosa biopsy sample’s data 
Olfactory mucosa biopsy samples from nine age- and gender-matched control and Schizophrenia subjects were 
used (Matigian et al., 2010). The microarray expression dataset was analyzed using Pathway Studio 8.0. 2487 
genes (p<0.05) were significantly differentially expressed between schizophrenia and control samples. The 
expression dataset was also subjected to the “Core analysis” and “Comparison analysis” of Ingenuity Pathway 
Analysis (IPA) software, version 9.0 (Ingenuity, 2010). 186 different molecular pathways were significantly 
altered in Schizophrenia, the top ten of which are shown in Table 1. It should be noted that the data in Table 1 
differ considerably from those reported in (Matigian et al., 2010), where the old IPA version 6.0 has been used. 
The 2487 significantly differentially expressed genes were compared with the 115 predicted gene list, 
finding 22 shared genes (ACHE, CAMK2A, CD4, CREB1, CTNNB1, EP300, FGF2, GNAS, GRM1, GRM5, 
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INS, MAPK1, NR3C1, OPRM1, PPM1A, PPP2CB, PRKACA, PTK2, RB1, SHC1, TGFB1, and YWHAE). 
Of these 22 genes, four encodes for transcription factors, protein kinase and receptor proteins each, three for 
ligands, two for phosphatases. All 22 genes except FGF2 directly interact with each other.  
 
Table 1 Molecular signaling pathways significantly altered in microarray expression datasets  
 
Olfactory mucosa 
biopsy sample 
Post-mortem brain 
tissue sample 
Ingenuity Canonical Pathways  p-value  p-value 
G-Protein Coupled Receptor Signaling
1 <  0.001  0.0052 
Axonal Guidance Signaling  < 0.001  < 0.001 
Molecular Mechanisms of Cancer  < 0.001  < 0.001 
Protein Kinase A Signaling  < 0.001  < 0.001 
Role of Macrophages, Fibroblasts and Endothelial Cells in 
Rheumatoid Arthritis  < 0.001  < 0.001 
Glucocorticoid Receptor Signaling
2 0.0034  <0.001 
Purine Metabolism
3 0.0032  0.0013 
Protein Ubiquitination Pathway
4   insignificant  0.0389 
Xenobiotic Metabolism Signaling
5   0.0020  0.0263 
Colorectal Cancer Metastasis Signaling  < 0.001  < 0.001 
Pathways are selected statistically using Fisher’s exact test (p- value). Refer 
1Bychkov et al., 2011;
 2 Webster et al., 2002;
 3 
Yao et al., 2010;
 4 Altar et al., 2005;
 5 Gassó et al., 2010. 
 
 
Fig. 2 The shortest-path network of 22 schizophrenia-related validated protein-encoding genes (highlighted in orange). The 
proteins are shown according to their location in the extracellular space, cell membrane, cytoplasm and nucleus. The protein-
protein interactions are correspondingly: binding (167 interactions represented by purple solid line), direct regulation (46, gray 
solid line), promoter binding (26, green solid arrow), protein modification (74, yellow solid arrow). 
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Different close network environment like shortest-path, common target and common regulator networks 
were built and the results were analyzed. Genes like MAPK1, CTNNB1, FGF2, EP300, CREB1, SHC1, PTK2, 
GRM5, NR3C1, and ESR1 acts as major hubs in the shortest-path network (see Fig. 2). EP300, MAPK1, 
CREB1, NR3C1, and CTNNB1 are highly targeted nodes. CTNNB1, CREB1, EP300, PTK2, and RB1 were 
highly connected key regulators of schizophrenia-related genes. The local connectivity (node degree) values of 
the 22 validated genes in the four networks built are shown in the Table 2.  
Two of the 22 validated genes (MAPK1, and NR3C1), which were found in our highly connected targets 
and regulators networks, were also implicated in other studies to have elevated expression in various mental 
disorder conditions like Schizophrenia, Bipolar disorder and Depression (Webster et al., 2002; Kyosseva et al., 
1999). Like other previous studies, our data also showed altered expression of ACHE, CAMK2A, CD4, FGFR, 
GNAS, GRM1, GRM5, OPRM1 and YWHAE, suggesting immunological abnormalities (Cazzullo et al., 
1998), possible use of ACHE inhibitors in improving cognitive impairment (Stip et al., 2007), altered 
expression of many neuroreceptors (Novak et al., 2006), corticostriatal plasticity and antagonizing the 
signaling pathway of dopamine receptors (Terwisscha van Scheltinga et al., 2010), alterations in intracellular 
G-protein signaling (Minoretti et al., 2006) and in glutamate receptors (Raw et al., 2010), modulation in 
neurotransmitters response (Devon et al., 2001), and  various neurodevelopmental abnormities (Serý et al., 
2010; Ikeda et al., 2008) in Schizophrenia subjects. 
 
Table 2 Local connectivity (node degree) of the  22 Schizophrenia-related validated genes in different 
Pathway Studio networks 
Name Codes  for  DI  SP  CT  CR 
ACHE Protein  1  8  1  6 
CAMK2A Protein  kinase  3  8  10  4 
CD4 Receptor  4  8  7  9 
CREB1 Transcription  Factor  14  25  93  39 
CTNNB1 Protein  7  32  38  54 
EP300 Transcription  Factor  11  29  122  38 
FGF2 Ligands  0  31  0  5 
GNAS Protein  1  10  1  9 
GRM1 Receptor  1  14  2  5 
GRM5 Receptor  1  19  4  2 
INS Ligands  4  7  5  15 
MAPK1 Protein  kinase  10  37  101  31 
NR3C1 Transcription  Factor  9  19  47  27 
OPRM1 Receptor  1  11  1  10 
PPM1A Phosphatase  1  4  8  0 
PPP2CB Phosphatase  2  8  11  4 
PRKACA Protein  kinase  2  11  3  0 
PTK2 Protein  kinase  4  21  14  37 
RB1 Transcription  Factor  5  10  31  35 
SHC1 Protein  4  25  8  31 
TGFB1 Ligands  2  15  3  14 
YWHAE Protein  1  5  4  2 
                   DI – Direct interaction; SP – Shortest-path; CT – Common targets; CR – Common regulators networks 
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The 22 validated genes were also subjected to the “core analysis” of the IPA 9.0 software. Many molecular 
pathways were found to be significantly altered in Schizophrenia, including CREB Signaling in Neurons, 
Synaptic Long Term Potentiation pathway, and PPARa/RXRa Activation.  
3.3 Validation of the set of 115 predicted genes by the post-mortem brain tissue sample’s data 
We used 20 age- and gender- matched control Schizophrenia post-mortem brain tissue samples (Higgs et al., 
2006).  The microarray expression dataset was analyzed using Pathway Studio 8.0, finding 1071 gene 
expression significantly (p<0.05) modulated in schizophrenia compared to control samples. The expression 
dataset was also subjected to the “Core analysis” and “Comparison analysis” of the IPA 9.0 software. Nearly 
180 different molecular pathways were significantly altered in Schizophrenia; the top ten are shown in the 
Table 1. Eleven from those 1071 genes were shared with the 115 genes predicted in Section 3.1 (See Table 1). 
Different close network environments of the 11 shared genes were used to build expanded networks by 
connecting them along the shortest possible paths with involvement of additional connecting proteins, as well 
as connecting them to their common regulators or their common targets. In the shortest path network (See Fig. 
3) all 11 genes were connected to each other, with ESR1, GSK3B, MAPK8, PPM1A, and CREB1 genes acting 
as major hubs. CREB1, MAPK8, ESR1, GSK3B, and PGR were both highly targeted and highly involved in 
regulation of other genes. The local connectivities (node degrees) of the 11 gene’s in the created four networks 
are shown in the Table 3.  
 
 
 
 
 
 
 
 
 
 
 
                                 DI – Direct interaction; SP – Shortest-path; CT – Common targets; CR – Common  
regulators networks 
 
The GSK3B protein, recently related to schizophrenia (Lovestone et al., 2007; Souza et al., 2008), was 
identified as a major hub of transcription factors regulation. CREB protein stimulates the expression of a 
number of genes. Also, any alterations in CREB expression may be associated with schizophrenia, including 
the regulation of dopamin (Kawanishi et al., 1999). Previous studies show that variations in the ESR1 gene are 
associated with schizophrenia (Weickert et al., 2008). 
The 11 validated genes were also subjected to the “core analysis” of IPA 9.0 software.  Many molecular 
pathways were significantly altered in the examined Schizophrenia post mortem samples, with Cardiac 
Hypertrophy Signaling being heavily altered, followed by typical schizophrenia-involved pathways like 
Glucocorticoid Receptor Signaling, Wnt/b-catenin Signaling, and ILK Signaling. 
 
 
 
 
 
Table 3 Local connectivity (node degree) of the 11 Schizophrenia-related validated 
genes in different Pathway Studio networks 
Name Codes  for  DI  SP  CT  CR 
CANX Protein  1  3  3  1 
CREB1 Transcription  Factor 8  18  54  22 
ESR1 Transcription  Factor  7  24  46  27 
GNAQ Protein  0  3  0  1 
GSK3B Protein  kinase  4  22  42  16 
MAPK8 Protein  kinase  3  21  47  9 
NCK1 Protein  0  5  2  4 
PGR Transcription  Factor  4  8  16  20 
PPM1A Phosphatase  0  21  9  0 
PPP2CB Phosphatase  1  7  6 2 
TGFBR1 Receptor  0  13  5 4 
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Fig. 3 Eleven Schizophrenia-related validated gene’s shortest-path network. The protein-protein interactions shown are: binding 
(55 interactions represented by purple line), direct regulation (11, gray line), promoter binding (6, green arrow), protein 
modification (59, yellow arrow). All 11 Validated genes (highlighted in blue) are connected.  
 
 
The most highly altered molecular and cellular functions included the reproductive System, with 
reproductive hormones possibly contributing to the onset
 of schizophrenia (Stevens et al., 2002), while another 
link being the extremely low fertility of schizophrenia subjects (Ritsner et al., 1992). Endocrine system, known 
to malfunction in schizophrenia both centrally and peripherally was found to be the next highly modulated 
system (Riecher-Rössler et al., 1993).  
3.4 Concluding analysis 
We found 157 genes that were significantly differentially expressed in both olfactory mucosa sample and post-
mortem brain tissue samples. Three of those genes, namely CREB1, PPM1A, and PPP2CB, were also found in 
most of our network-based datasets and may be expected to belong to an essential part of the molecular 
mechanisms of schizophrenia. Although not included in the list of 38 basic schizophrenia-related genes (Allen 
et al., 2008, Ross et al., 2006), they all have been previously associated with schizophrenia. CREB1 was 
briefly discussed in the previous subsection, PPM1A is considered potential therapeutic agent for the 
prevention or treatment of schizophrenia (Bahn et al., 2006), and PPP2CB has also been briefly related to it 
(Marvanova et al., 2004). However, we identified five genes (GNAQ, NCK1, PGR, SHC1, and TGFBR1) for 
which no previously reported relation to schizophrenia was found.  
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Ten genes (ADRB2, ARRB1, CAV1, CD44, CDK5, DNM1, ESR1, FYN, PRKCB, and SRC) from the 
115 schizophrenia-related ones predicted in Section 3.1 emerged also in the shortest-path network built for the 
22 validated genes. Similarly, three from the 115 predicted genes (ARRB1, MAPK14, and MAPK9) were 
found included in the shortest-path network built for the 11 validated genes. Two other predicted genes (CD44 
and PRKCB) have not yet being related to Schizophrenia. Our systems biology approach thus expanded the 
pool of genes potentially related to schizophrenia, as a basis for further efforts to elucidate the molecular and 
cellular mechanisms of Schizophrenia.  
Irrespective of their very different nature, the two microarray expression analyses identified the same 
molecular pathways that were the most deregulated in patients samples. They all have been implicated in 
Schizophrenia, to mention few of them: G-Protein Coupled Receptor Signaling, Glucocorticoid Receptor 
Signaling, Purine Metabolism, Protein Ubiquitination Pathway, Xenobiotic Metabolism Signaling, and Cardiac 
Hypertrophy Signaling (Bychkov et al., 2011; Webster et al., 2002; Yao et al., 2010; Altar et al., 2005; Gassó 
et al., 2010].  
The detailed information on schizophrenia related genes and cellular processes provided by our study 
indicates the potential of the systems biology approach when applied as shown in Fig. 1 to an expanded space 
of disease genes. This expansion of the seed sets of genes found from literature search and microarray analysis 
was performed by using their immediate network environment of various regulatory, binding and other 
interactions. Such an integrative process offers better chances to identify the key players in the disease, and to 
offer ways to suppress them. 
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